Eldon Mayer is a seasoned leader who brings extensive experience in building and managing high-performance commercial teams, as well as product launch planning and lifecycle management.
Prior to joining Eiger, Mr. Mayer was Executive Vice President and Chief Commercial Officer of Rigel Pharmaceuticals where he built and led the commercial organization of over 60 people and the successful launch of Tavalisse (fostamatinib disodium hexahydrate) for chronic immune thrombocytopenia, a rare disease. Previously, Mr. Mayer was Senior Vice President of Commercial Operations at Questcor Pharmaceuticals, focused on serious, rare diseases, where he built and managed a commercial team of over 400 people, successfully commercialized Acthar Gel (repository corticotropin injection), and grew annual sales to over $1 billion. Questcor was acquired by Mallinckrodt for $5.6 billion in 2014. Earlier in his career, he held positions of increasing responsibilities at companies including Schering-Plough, ALZA, Chiron, and Connetics, in functional areas including strategic planning, marketing, sales, market research and analytics, operations, and finance. Mr. Mayer has served as a member of the board for Eiger BioPharmaceuticals, Inc., Promet Therapeutics, LLC, and the National Community Oncology Dispensing Association.
Mr. Mayer holds a BS in Finance from Fairleigh Dickinson University and an MBA in Marketing from Syracuse University.
What is Eldon C. Mayer, III's net worth?
The estimated net worth of Eldon C. Mayer, III is at least $0.00 as of March 17th, 2023. Mr. Mayer, III owns 1,869 shares of Eiger BioPharmaceuticals stock worth more than $0 as of April 25th. This net worth estimate does not reflect any other investments that Mr. Mayer, III may own. Learn More about Eldon C. Mayer, III's net worth.
How do I contact Eldon C. Mayer, III?
Has Eldon C. Mayer, III been buying or selling shares of Eiger BioPharmaceuticals?
Eldon C. Mayer, III has not been actively trading shares of Eiger BioPharmaceuticals within the last three months. Most recently, Eldon C. Mayer III sold 146 shares of the business's stock in a transaction on Friday, March 17th. The shares were sold at an average price of $32.10, for a transaction totalling $4,686.60. Following the completion of the sale, the vice president now directly owns 1,869 shares of the company's stock, valued at $59,994.90. Learn More on Eldon C. Mayer, III's trading history.
Who are Eiger BioPharmaceuticals' active insiders?
Are insiders buying or selling shares of Eiger BioPharmaceuticals?
During the last twelve months, Eiger BioPharmaceuticals insiders bought shares 2 times. They purchased a total of 5,940 shares worth more than $44,170.20. The most recent insider tranaction occured on November, 2nd when Major Shareholder Richard A Kayne bought 779 shares worth more than $7,011.00. Insiders at Eiger BioPharmaceuticals own 4.2% of the company.
Learn More about insider trades at Eiger BioPharmaceuticals. Information on this page was last updated on 11/2/2023.
